Quarterly report · Q2
2112.TEDINET S100S41D
Period2023-04-01 → 2023-09-30
Filed2023-11-02
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥15.6bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥27.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥13.4bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥546m | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥274m | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥1.2bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥731m | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥244m | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.2bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥244m | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥901m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥498m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥138m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥901m | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥138m | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥26.2bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥25.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥25.2bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥13.7bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥14.8bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥12.5bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥11.0bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥10.4bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.4bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.2bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.4bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.2bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.3bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.5bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥434m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥447m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥104m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥76m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥374m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥172m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥1.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥33.01 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥0.48 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥18.28 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥5.1 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.14 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 47.7% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.6% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.2% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2023-04-01 → 2023-09-30 | ¥67m |
| Otherother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥59m |
| Otherother segments | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥8m |
| Otherother segments | segment profit | 2023-04-01 → 2023-09-30 | ¥37m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥59m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥59m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥621m |
| jpcrp040300-q2r_E00361-000Biotechnologyreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥964m |
| jpcrp040300-q2r_E00361-000Biotechnologyreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥927m |
| jpcrp040300-q2r_E00361-000Biotechnologyreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥37m |
| jpcrp040300-q2r_E00361-000Biotechnologyreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥211m |
| jpcrp040300-q2r_E00361-000Sugarreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥14.6bn |
| jpcrp040300-q2r_E00361-000Sugarreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥14.6bn |
| jpcrp040300-q2r_E00361-000Sugarreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥13m |
| jpcrp040300-q2r_E00361-000Sugarreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥919m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥15.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥15.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥59m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥1.2bn |
| Otherother segments | revenue | 2022-04-01 → 2022-09-30 | ¥67m |
| Otherother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥59m |
| Otherother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥8m |
| Otherother segments | segment profit | 2022-04-01 → 2022-09-30 | ¥30m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥55m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥55m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥577m |
| jpcrp040300-q2r_E00361-000Biotechnologyreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥925m |
| jpcrp040300-q2r_E00361-000Biotechnologyreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥891m |
| jpcrp040300-q2r_E00361-000Biotechnologyreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥34m |
| jpcrp040300-q2r_E00361-000Biotechnologyreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥238m |
| jpcrp040300-q2r_E00361-000Sugarreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥12.4bn |
| jpcrp040300-q2r_E00361-000Sugarreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥12.4bn |
| jpcrp040300-q2r_E00361-000Sugarreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥13m |
| jpcrp040300-q2r_E00361-000Sugarreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥582m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥13.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥13.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥55m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥851m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 498
| Item | Context | Value | Unit |
|---|---|---|---|
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00361-000BiotechnologyReportableSegmentsMember | 34000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_OtherReportableSegmentsMember | 8000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 55000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -55000000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00361-000SugarReportableSegmentsMember | 12448000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00361-000BiotechnologyReportableSegmentsMember | 925000000 | JPY |
| Net sales | Prior1YTDDuration_OtherReportableSegmentsMember | 67000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 13440000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -55000000 | JPY |
| Net sales | Prior1YTDDuration | 13384000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00361-000SugarReportableSegmentsMember | 582000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00361-000BiotechnologyReportableSegmentsMember | 238000000 | JPY |
| Operating income | Prior1YTDDuration_OtherReportableSegmentsMember | 30000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 851000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -577000000 | JPY |
| Operating income | Prior1YTDDuration | 274000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00361-000SugarReportableSegmentsMember | 14579000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00361-000BiotechnologyReportableSegmentsMember | 927000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_OtherReportableSegmentsMember | 59000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 15566000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 15566000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00361-000SugarReportableSegmentsMember | 13000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00361-000BiotechnologyReportableSegmentsMember | 37000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_OtherReportableSegmentsMember | 8000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 59000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -59000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00361-000SugarReportableSegmentsMember | 14593000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00361-000BiotechnologyReportableSegmentsMember | 964000000 | JPY |
| Net sales | CurrentYTDDuration_OtherReportableSegmentsMember | 67000000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 15625000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -59000000 | JPY |
| Net sales | CurrentYTDDuration | 15566000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00361-000SugarReportableSegmentsMember | 919000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E00361-000BiotechnologyReportableSegmentsMember | 211000000 | JPY |
| Operating income | CurrentYTDDuration_OtherReportableSegmentsMember | 37000000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 1168000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -621000000 | JPY |
| Operating income | CurrentYTDDuration | 546000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2023-11-02 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第91期第２四半期(自 2023年７月１日 至 2023年９月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)塩水港精糖株式会社 | |
| Company name in english cover page | FilingDateInstant | Ensuiko Sugar Refining Co., Ltd. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 木 村 成 克 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都中央区日本橋堀留町二丁目９番６号 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |